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Kikumi Ogihara1, Yuko Naya1, Yoshiharu Okamoto2 and Keishi Hata3*Abstract
Canine melanoma is the most common oral malignant tumor reported in the field of veterinary medicine. We
found that lupeol, a lupine triterpene, inhibited mouse melanoma cell growth in vitro and in vivo by inducing cell
differentiation. In the present study, we examined the differentiation-inducing activities of lupeol on 4 canine
melanoma cells in vitro and in vivo.
The induction of canine melanoma cell differentiation by lupeol was confirmed by evaluating some differentiation
markers such as tyrosinase with real-time RT-PCR. Furthermore, we transplanted canine melanoma cells into a
severe combined immunodeficiency mouse, and studied the anti-progressive effects of lupeol on tumor tissue.
The gene expression of microphthalmia-associated transcription factor, tyrosinase, and tyrosinase-related protein-2,
which are markers of pigment cell differentiation, was induced in 4 canine oral malignant melanoma cells by lupeol,
and the agent markedly inhibited tumor progression in canine melanoma-bearing mice.
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Melanoma is the most aggressive form of skin cancer that
is derived from activated or genetically altered epidermal
melanocytes (Oliveria et al. 2001). Human malignant mel-
anoma is a highly metastatic cancer that is markedly resist-
ant to chemotherapy with dacarbazine or temozolomide.
Canine melanoma is the most common oral malignant
tumor reported in the field of veterinary medicine
(Bergman, 2007). It was reported that treatment of car-
boplastin significantly affects dogs with malignant mel-
anoma, and achieved a response rate at 28% (Rassnick
et al. 2001).
Lupeol, a plant pentacyclic triterpene, was previously
shown to have various biological activities, such as anti-
inflammatory (Fernández et al. 2001a,b), anti-cancer
(Saleem 2009), and anti-metabolic syndrome (Sasaki et al.
2008; Hata et al. 2008; Itoh et al. 2009) activities. We previ-
ously demonstrated that lupeol inhibited mouse melanoma
cell growth by inducing melanogenesis and suppressing
the motility of cells (Hata et al. 2006). These findings re-
vealed that lupeol induced the differentiation of melanoma* Correspondence: hata@arif.pref.akita.jp
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in any medium, provided the original work is pcells into mature melanocyte-like cells in vitro. In our re-
cent study, we showed that lupeol suppressed tumor
growth in melanoma-bearing mice by attenuating prolifer-
ating cell nuclear factor (PCNA) and Ki67, which are
highly expressed in melanoma or other tumors (Nitta et al.
2013). However, the effects of lupeol on other melanoma
such as canine melanoma remain unclear. In the present
study, we examined the differentiation-inducing activities of
lupeol on canine melanoma cells in vitro and its anti-
melanoma effects in vivo, prior to clinical trials on canine
melanoma.Material and methods
Cell culture
With prior written informed consents of animal owners, 4
melanoma samples were separately harvested after surgi-
cal procedures, and 4 canine oral malignant melanoma
(cMEL) cell lines were established from these tumor sam-
ples. The three melanoma cell lines (cMEL-1, −3, and −4)
were maintained in Dulbecco’s modified Eagle’s medium,
and cMEL-2 cells were maintained in RPMI-1640 medium,
respectively, supplemented with 10% fetal calf serum,
100 μg/ml of streptomycin, and 100 U of penicillin.an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Aliquots of 1 ml of cMEL-1-4 cells (1 × 104 cells) were
incubated with various concentrations of lupeol (Sigma-
Aldrich, INC.) for 4 days, and the number of viable cells
was counted by trypan blue exclusion method. IC50
values, representing the concentration that inhibited
melanoma cell growth by 50%, were measured.RNA extraction and cDNA synthesis
Canine melanoma cells (2 × 104 cells) in 10 cm-dishes
(10 ml) were incubated with or without lupeol for 2 days.
Total RNA was isolated using the QuickGene RNA cul-
tured cell kit S (FUJIFILM, Co.). Template cDNA syn-
thesis was performed with 5 μg of total RNA using the
PrimeScript RT Reagent Kit (TAKARA BIO, INC.)Real-time RT-PCR
In a fluorescent temperature cycler (Chromo4; Bio-Rad
Laboratories, Inc.), 2.5% of each RT reaction solution was
amplified in 25 μl of 1 × SYBR Premix Ex Taq (TAKARA
BIO, INC.) containing 0.2 μM of each primer. Samples
were incubated in the thermal cycler for an initial denatur-
ation at 95°C for 10 s, followed by 40 PCR cycles. Each
cycle consisted of 95°C for 5 s and 60°C for 30 s. The
oligonucleotide primers used in the present study are indi-
cated in Table 1. To confirm the amplification of specific
transcripts, melting curve profiles (cooling the sample to
60°C and heating slowly to 95°C with the continuous
measurement of fluorescence) were produced at the end
of each PCR. The relative expression level of each mRNA
was normalized by the amount of GAPDH mRNA.Table 1 Oligonucleotide primers used in real-time RT-PCR













GAPDH Glyceraldehyde-3-phosphate dehydrogenase, MITF microphthalmia-
associated transcription factor, TYR tyrosinase, TRP-2 tyrosinase-related protein
2, PCNA proliferating cell nuclear factor, S sense, A; antisense.Subcutaneously administration of lupeol to canine
melanoma-bearing mice
C.B-17/Icr-scid/scid Jc severe combined immunodeficiency
(SCID) mouse were obtained from Crea Japan, INC.. A total
of 1×107 cMEL-2 cells were subcutaneously injected into
the back regions of SCID mice. Mice whose tumors grew to
10 mm in size were used in this study (day 0). Fifteen mice
were randomized into 3 groups on day 0 (n = 5/group). Tu-
mors were removed from 5 mice on day 0 and their weights
were measured (day 0 group). Single injections of olive oil
(0.1 ml, vehicle control group) or 0.5 mg lupeol in 0.1 ml
olive oil (lupeol group) were subcutaneously administered
around tumor tissue of each mouse at day 0. The tumor tis-
sues of each mouse were removed 10 days after the injec-
tions, and their weights were measured. The experimental
plan of the study was approved by the Ethics Committee
for Animal Experimentation of Azabu University.
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD). The significance of differences was analyzed using
the Student’s t-test (Figures 1, 2, 3) and one-way ANOVA
with Tukey’s multiple comparison test (Figure 4). A value
of p < 0.05 was considered significant.
Results and discussion
We investigated whether lupeol induced the differentiation
of canine oral malignant melanoma (cMEL) cells by evalu-
ating some differentiation markers with real-time RT-PCR.
Figure 1 shows the effects of 5 μM lupeol on the gene ex-
pression of microphthalmia-associated transcription factor
(MITF), tyrosinase (TYR), and tyrosinase-related protein-2
(TRP-2) in 4 canine melanoma cells. Lupeol up-regulated
MITF genes 1.5-3.1-fold, TYR genes 1.8-5.7-fold, and TRP-
2 genes 1.9-3.9-fold, respectively, which indicated that the
agent induced the differentiation of canine melanoma cells
as well as mouse melanoma cells.
The proliferation of 4 canine melanoma cells was
markedly suppressed by 10 μM lupeol, and this agent
exhibited particularly strong anti-proliferative effects on
cMEL-1 and −2 cells (Figure 2). The IC50 values of
lupeol against 4 melanoma cells were 5.6 μM (cMEL-1),
2.3 μM (cMEL-2), 15.7 μM (cMEL-3), and 15.7 μM
(cMEL-4), respectively; however, even at each IC50, all
melanoma cells did not detach and remained >95% vi-
able, suggesting that the inhibition of cell growth by
lupeol can be attributed to its cytostatic (differentiation-
inducing), but not cytotoxic effects.
PCNA is a cell-cycle regulator expressed in the nu-
cleus of proliferating cells. The degree of PCNA expres-
sion has been correlated with tumor progression and
grade in some tumors (Zeng and Davis 2003; Hall et al.
1990; Malham et al. 2010). Ki67 is also a cell proliferation























































































Figure 1 Up-regulation of melanoma cell differentiation markers by lupeol. Four canine melanoma cells (2 × 105 cells) were treated
without (white bar) or with 5 μM lupeol (gray bar) for 48 h, and the gene expression of MITF, TYR, and TRP-2 was measured by real-time RT-PCR.
* p < 0.05, ** p < 0.01 vs untreated cells (n = 3).





















Figure 2 Antiproliferative activity against 4 canine melanoma cells. Canine melanoma cells (1 × 104 cells) were treated without (white bar)
or with 10 μM lupeol (gray bar) for 4 days, and the viable cell number was subsequently counted by the Trypan blue exclusion method. * p < 0.05,

























































Figure 3 Attenuation of the expression of PCNA and Ki67 genes by lupeol. Four canine melanoma cells (2 × 105 cells) were treated without
(white bar) or with lupeol at IC50 values against each melanoma cell (gray bar) for 48 h, and the gene expression of PCNA and Ki67 was
measured by real-time RT-PCR. ** p < 0.01 vs untreated cells (n = 3).




















Figure 4 Suppressive effects of the systemic administration of lupeol on tumor growth in melanoma‑bearing SCID mice. Single
injections of olive oil (vehicle control group; Vehicle) or lupeol (lupeol group; Lupeol) were subcutaneously administered to each mouse on day 0.
The weights of tumor tissues were measured 10 days after the injections. ** p < 0.01 between each group (n = 5).
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of malignancy and prognosis (Gould Rothberg et al. 2009).
We previously reported that lupeol suppressed the expres-
sion of PCNA and Ki67 in B16 mouse melanoma cells
both in vitro and vivo. Therefore, we studied the effects of
lupeol at each IC50 value against canine melanoma cell
growth on the expression of PCNA and Ki67 genes. Real-
time RT-PCR analysis revealed that lupeol suppressed the
expression of PCNA and Ki67 in 4 canine melanoma cells
by 47.4-68.0% and 43.4-62.5%, respectively (Figure 3).
Furthermore, we transplanted cMEL-2 cells into a
SCID mouse, and studied the anti-progressive effects of
lupeol on tumor tissue (Figure 4). Although the melan-
oma was 5.7-fold bigger by day 10, growth was signifi-
cantly suppressed by 78.7% that of the vehicle control
with the single administration of lupeol (p < 0.01). We
administered lupeol to melanoma-bearing mice only
once in the present study, and a higher dose and/or re-
peated injection of lupeol appeared to be more effective
in treating the melanoma.
We demonstrated the differentiation-inducing and anti-
proliferative activities of lupeol on 4 canine melanoma
cells both in vitro and in vivo. We intend to establish a
nonsurgical treatment for canine melanoma with lupeol
based on these results.Competing interests
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